HIV Infections Clinical Trial
Official title:
Impact of Peer Health Workers and Mobile Phones on HIV Care
The provision of antiretroviral therapy (ART) in rural, resource-limited settings entails
substantial challenges due to limitations in the health service infrastructure and in human
resources for HIV/AIDS care. In addition, long geographical distances between providers,
care facilities, and patients can represent a significant barrier to appropriate and timely
care. The use of peer health workers as frontline adherence supporters and clinical monitors
in order to improve care in underserviced settings has been implemented by a number of
programs, but the effect of peer support on HIV care outcomes has not been extensively
evaluated. Mobile phones have also been proposed as a potential method of improving access
to health care in resource-limited environments by expediting communication and data
transfer, but rigorous studies on their effectiveness in Africa have not yet been conducted.
The Rakai Health Science Project (RHSP) was founded in 1987 to study the HIV epidemic in the
rural setting of Rakai District in southwest Uganda. Since June 2004, the US President's
Plan for AIDS Relief (PEPFAR) has enabled the RHSP to provide ART through a community-based
distribution system which includes clinical monitoring via a decentralized, mobile clinic
approach. By late 2006, the program has screened 4,397 HIV-infected individuals and
initiated ART in 849 patients. One of the challenges of providing ART in this setting has
been the distance between many patients' homes and the clinic and medical staff trained in
HIV care. This distance and the lack of communication channels make frequent clinic contacts
difficult and has raised concerns about adherence and management of drug toxicity. This
study will investigate whether peer health workers can help support this AIDS care program
and improve patient outcomes.
This study is a three armed, community-randomized operations research trial to assess the
effectiveness of peer health workers, with and without mobile phones, in improving the
delivery of HIV care in the resource-limited Rakai setting. The three arms will be: a)
communities with peer health workers, b) communities with peer health workers and mobile
phones, and c) control communities without peer health workers.
Study hypotheses include:
- Peer health workers, by supporting adherence and by managing simple clinical issues,
will reduce virologic treatment failure and improve ARV adherence compared to patients
in communities without peer educators.
- Mobile phone technology used by peer health workers, by more rapidly addressing
adherence and clinical problems, will reduce treatment failure and improve adherence
compared to patients in communities with peer health workers without mobile phones.
| Status | Completed |
| Enrollment | 1200 |
| Est. completion date | January 2012 |
| Est. primary completion date | April 2008 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - Inclusion in the study is determined by receipt of ARVs in the PEPFAR program. Exclusion Criteria: |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Johns Hopkins University | Doris Duke Charitable Foundation, MRC/UVRI Uganda Research Unit on Aids, National Institute of Allergy and Infectious Diseases (NIAID) |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Virologic suppression at 6 months | 6 months | No | |
| Primary | Virologic failure at all time intervals from ART initiation (these primary outcomes added to expanded trial protocol November 2007) | Typically every 24 weeks | No | |
| Primary | Adherence measured by pill counts (this primary outcome added to expanded trial protocol November 2007) | Typically weekly to monthly | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |